Connected Injectable Drug Delivery Devices Market: Forecast (2017-2023)

NEW YORK, Nov. 20, 2017 /PRNewswire/ -- Connected injectable drug delivery devices reminds and records patients dosing pattern and makes it accessible to healthcare professionals for significant understanding about the patient condition. These drug delivery devices helps in addressing the patient consistence issues with the medication treatment, disease management protocols which are major concerns for healthcare professionals and pharmaceutical industry.

Read the full report: https://www.reportlinker.com/p05206633

Before bringing a connected health offering to life, it is important to understand the fundamentals of patient-centric design. One of the most successful elements in fulfilling the need for patient-centric design is human factors analysis, which benefits the patient by making injection systems more comfortable and user-friendly.

Connected injectable drug delivery devices market is comprehended by device type, technology, application and end user. By device type the market is further segmented into inhalation devices, injection devices, solid dosage forms and others.

Whereas injection devices are further sub segmented into handheld devices and wearable devices. Based on technology the market is categorized into Bluetooth, smart phone apps, near field communication (NFC) and emergency technologies. By application the market is further segmented into diabetes, cardiovascular diseases, autoimmune diseases, hormones replacement, neurology, addiction, respiratory diseases and others. Based on end users the market is categorized into hospitals, clinics and homecare settings.

Connected injectable drug delivery devices market is further analyzed on the basis of regions such as: North America, Europe, Asia-Pacific and Row.

Sample Companies profiled in this report are:
Phillips-Medisize Corporation (U.S.),
West Pharmaceutical Services, Inc. (U.S.),
Biocorp (France),
Aterica, Inc. (Canada),
Unilife Corporation (U.S.),
10+.

Growing prevalence of chronic diseases like diabetes, cardiovascular disease, and cancer coupled with increasing compliance to the treatment owing to use of these devices. Increased interest of pharmaceutical or medical devices companies to surge consumer compatibility and application is expected to propel the growth of the market in the near future.

The research methodology opted for this report incorporates initial segregation of the market by device type, technology, application, end user and region. This was followed by mining of market volume and revenue of different device type of connected injectable drug delivery devices employed by various applications with respect to regions is considered.

Bottom up approach was then followed for estimating the global market size and its forecast for period 2017 to 2023. The data figures and supporting insights so collated were validated through primary research process by Key Opinion Leaders (KOLs) which comprised of manufacturers, distributors, suppliers, associations and end users.

Read the full report: https://www.reportlinker.com/p05206633

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________
Contact Clare: clare@reportlinker.com
US: (339)-368-6001
Intl: +1 339-368-6001

View original content:http://www.prnewswire.com/news-releases/connected-injectable-drug-delivery-devices-market-forecast-2017-2023-300559784.html

SOURCE Reportlinker